These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 16381629

  • 21. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 22. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Sep 03; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 23. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 24. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 25. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
    Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL.
    Am J Hematol; 2015 Oct 15; 90(10):877-81. PubMed ID: 26149465
    [Abstract] [Full Text] [Related]

  • 26. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 15; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 27. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Aug 15; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 28. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 15; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 29. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Sep 15; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 30. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Sep 15; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 31. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 32. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC.
    J Nephrol; 2008 Feb 01; 21(4):543-9. PubMed ID: 18651544
    [Abstract] [Full Text] [Related]

  • 33. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 01; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 34. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC, Hung CC, Lee CT, Lee CH, Lee CC, Lin CL, Sun CY, Cheng BC, Yang CC, Wu CH, Chen JB.
    Ther Apher Dial; 2016 Aug 01; 20(4):400-7. PubMed ID: 27060362
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 01; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 36. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 01; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 37. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 01; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 38. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 01; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 39. [Study of effectiveness of 3 schedules of administration of erythropoietic colony-stimulating factors in anemic patients under chemotherapy for solid or hematology malignancy].
    Pontón Sivillá JL, Feliu Frasnedo E, Modamio Charles P, Mariño Hernández EL, Font Pous A, Lezcano Rubio C, Ribera Santasusana JM, Bonafont Pujol X.
    Med Clin (Barc); 2008 Oct 11; 131(12):447-51. PubMed ID: 18928734
    [Abstract] [Full Text] [Related]

  • 40. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec 11; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.